small molecule compounds

A unique collection of 2850 GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research;

A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.

A unique collection of 718 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A collection of 19170 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

120 well-chosen unique AMPK-targeted small molecules;

A unique collection of 861 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;

A unique collection of 631 nuclear receptor signaling targeted compounds for high throughput and high content screening;

Membrane proteins are a class of proteins widely found in biological cell membranes, playing essential roles in the structure and function of cells. Based on their location and function, membrane proteins can be classified into three main categories: peripheral membrane proteins, integral membrane proteins, and lipid-anchored proteins. Membrane proteins encompass a variety of functional proteins, including glycoproteins, carrier proteins, and enzymes. They are often linked to carbohydrate molecules, which can transmit signals into the cell by undergoing structural changes, participating in signal transduction processes. Membrane proteins perform a range of critical functions, including substance transport, signal transduction, cell recognition, and energy conversion. In drug development, membrane proteins, especially G protein-coupled receptors (GPCRs), ion channels, and transporters, are of particular interest. Many diseases are related to the malfunction of specific membrane proteins. Therefore, drugs designed to target these proteins can regulate their activity, aiming to treat diseases. TargetMol has collected 6422 compounds that target membrane proteins, which can be used for membrane protein-related scientific research and drug screening, suitable for high-throughput and high-content screening.

A unique collection of 573 cancer cell differentiation inducing compounds for high throughput and high content screening;

A unique collection of 1220 compounds targeting ion channels for research in ion channels-related diseases and ion channel drug discovery;

A unique collection of 941 glutamine metabolism related compounds can be used for high throughput screening (HTS) and high content screening (HCS), and also is an effective tool for research in glutamine metabolism and cancer;

A unique collection of 280 bioactive compounds specifically targeting adrenergic receptors, effective tool for screening new drugs or new target identification;

1264 small molecule compounds with pro-oxidant or anti-oxidant activity for high-throughput and high-content screening.

Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species (ROS) and a biological system's ability to readily detoxify the reactive intermediates or repair the resulting damage. Disturbances in the normal redox state of cells can cause toxic effects through the production of peroxides and free radicals that damage all components of the cell, including proteins, lipids, and DNA. In humans, oxidative stress is thought to be involved in the development of atherosclerosis, heart failure, myocardial infarction, cancer, infection etc. Antioxidants are a class of compounds that counteract oxidative stress and reduce oxidative damage. The TargetMol Antioxidant Compound Library is a unique collection of 2010 small molecules with inhibitory effects on oxidative stress and is a useful tool for high-throughput screening and high-content screening in the study of oxidative stress.

A unique collection of 1470 compounds with defined autophagy-inducing or -inhibitory activity for research in autophagy, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 701 preclinical compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1332 clinical failed compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 569 histone modification related compounds for high throughput screening (HTS) and high content screening (HCS);

128 methylation-related compounds that can be used for high-throughput and high-content screening.

A unique collection of 815 compounds targeting cytokine signaling for high throughput screening and high content screening for drug discovery;

A unique collection of 530 JAK/STAT signaling targeted compounds for high throughput and high content screening;

A unique collection of 1120 compounds targeting NF-κB signaling for high throughput screening and high content screening;

A unique collection of 1440 DNA Damage & Repair related compounds for high throughput screening (HTS) and high content screening (HCS);

Offers 910 small molecules that enhance gene editing efficiency, suitable for high-throughput screening (HTS) and high-content screening (HCS);